



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

**MINUTES OF THE MEETING HELD ON WEDNESDAY 20TH FEBRUARY 2019
AT 12.00pm**

**IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr T Mackenzie (TM)	GP, EL CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2019/013: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG

2019/014: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2019/015: MINUTES OF JANUARY MEETING:

Accepted as a correct record.

2019/016: MATTERS ARISING:

2018/052: LMMG Recommendations (from Feb LMMG) - Melatonin guidelines – VG
following up with specialist.

2018/164: Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance®, Clinitas Multi® - further information being prepared by ophthalmology. Representative from ophthalmology to attend March ELMMB meeting.

2019/007: LMMG Recommendations (from Dec LMMG) - Choice of DOAC for stroke prevention in AF Position Statement – to be combined with memo from LMMG and brought back to ELMMB.

2019/017: NEW PRODUCT REQUEST – CICLESONIDE INHALER

Ciclesonide inhaler requested by Dr I Crossingham, Consultant Respiratory Physician, as a treatment option in asthma for those who continue to have exacerbations despite other step 4 therapies. Agreed to add to formulary as an option for secondary care initiation.

Resolved: Ciclesonide inhaler approved for addition to formulary for secondary care initiation.
Traffic Light: Amber

2019/018: NEW PRODUCT REQUEST – GASTROGRAFIN FOR BOWEL OBSTRUCTION

Gastrografin requested by Mr Adnam Sheikh, Consultant Colorectal Surgeon, to aid the resolution of bowel obstruction without surgery. Gastrografin will reduce the need for surgery for many patients. Agreed to add to formulary, for prescribing by senior clinician only, to aid resolution of bowel obstruction in acute setting.

Resolved: Gastrografin added to formulary for use by senior clinician for bowel obstruction
Traffic Light: Red

2019/019: NEW PRODUCT REQUEST – PALACOS R+G FAST®

Palacos R+G Fast® is a bone cement with gentamicin requested by Mr V Shah, Consultant Orthopaedic Surgeon, to use in orthopaedic surgical procedures. This is a fast setting product with higher elution rate of antibiotic, superior properties and is to replace the current product. Agreed to add to formulary as a replacement for CMW 2G bone cement.

Resolved: Palacos R+G Fast to replace CMW 2G bone cement on formulary.
Traffic Light: Red

2019/020: UNLICENSED PRODUCT REQUEST – BENZBROMARONE

Benzbromarone (unlicensed), requested by Prof Teh, Consultant Rheumatologist, for use as uricosuric agent for patients with severe adverse reaction to other licensed agents. Has been agreed by chairman's action for one patient to initiate treatment. Agreed for use on a named patient basis by specialists.

Resolved: Benzbromarone added to formulary on specialist initiation only.
Traffic Light: Red

2019/021: LMMG CONSULTATIONS (for March LMMG)

Ospemifene for the treatment of moderate to severe symptomatic vulvar & vaginal atrophy in post-menopausal women who are not candidates for local vaginal oestrogen therapy consultation. The proposed black traffic light recommendation is supported.

RMOG Homely Remedy Template Policy for use in Care homes. This policy was not considered to be practical. The current local policy is established and meets local requirements. Current policy shared with LMMG along with the response from the CCG.

Resolved: Responses sent / to be sent to LMMG.

2019/022: LMMG RECOMMENDATIONS (from Jan LMMG)

Cannabis-based Medicinal Products for Chronic Pain Position Statement – accepted as written for use in ELHE.

Asthma Treatment Guideline – updated – not adopted - to continue to use ELHE guideline.

2019/023: FORMULARY UPDATES

Cilique® – to be added to formulary to replace Cilest® which is being discontinued.

Traffic Light: Green

Ganciclovir eye gel – to be added to formulary to replace acyclovir eye ointment which is being discontinued.

Traffic Light: Green

Epimax® paraffin free ointment – added to formulary as an option when a paraffin free emollient is required.

Traffic Light: Green

Abidec & Sytron for premature neonates – to be continued up to 12 months of age for premature babies. Information to be included on formulary and communicated to GP's GP's

Traffic Light: Green

Brivaracetam – now licensed for use in children. Traffic light changed from red to amber.

Traffic Light: Amber

Vortioxetine – LCFT request to change from amber to green. LCFT to produce guidance/pathway to assist GP's and support initiation in primary care. Agreed change to green.

Traffic Light: Green

Pirenzepine – included in LCFT formulary as unlicensed use for clozapine hypersalivation. To be added to ELMMB formulary with red traffic light.

Traffic Light: Red

Gentamicin for nebulisation – now recommended by BTS for bronchiectasis. To be included on formulary along with supporting information.

Traffic Light: Amber

Resolved: Formulary to be updated as above

2019/024: UTI IN PRIMARY CARE – MICROGUIDE UPDATE

For information: Microguide has been updated for UTI in primary care with the changes, detailed in the summary paper, that were discussed at the antimicrobial stewardship committee. Updates acknowledged.

Resolved: UTI in Primary care – Microguide update acknowledged.

2019/025: ELHE: RESPIRATORY GUIDELINES - UPDATED

The guidelines have been updated following a meeting of interested parties from the CCGs and the trust.

COPD: Comments have been received suggesting removal of salmeterol/fluticasone combination MDI, inclusion of Symbicort® MDI and DPI, inclusion of a triple therapy DPI, and some more clarity regarding other options are available in secondary care. Comments to be considered for inclusion and amended guideline to be brought back to ELMMB

Action: COPD guideline to be amended

Asthma: Approved for use in ELHE.

Resolved: Asthma guideline accepted for use.

2019/026: GOSERELIN (ZOLADEX®) SHARED CARE - UPDATED

The Goserelin shared care documents (3.6mg and 10.8mg implants) have been updated in line with comments received. There was discussion regarding the monitoring requirements. Agreed to change wording to 'suggested monitoring'. ELMMB approved the shared care documents for use in ELHE.

Resolved: Goserelin (Zoladex®) 3.6mg & 10.8 mg Implants Shared Care Guidelines approved for use in ELHE.

2019/027: ANTIHISTAMINES PRESCRIBING POLICY

The CCG's antihistamines prescribing policy has been prepared to support self-care. Concerns were expressed that this policy does not take into account those patients who require higher dose antihistamines for conditions eg chronic urticaria. The policy to be amended to include clarity that high dose antihistamines advised by dermatology specialists or immunologists are excluded.

Action: Antihistamines prescribing policy to be amended.

2019/028: GUIDELINES FOR TABLETS CRUSHING

Document withdrawn from agenda.

2019/029: CYTOTOXICS – GUIDANCE FOR CARE HOMES

For information: This resource for care homes is to be uploaded to the website.

2019/030: GENERIC PRESCRIBING POSITION STATEMENT

The CCG generic prescribing position statement acknowledged. To be added to website.

2019/031: NICE RECOMMENDATIONS (from Jan)

Regorafenib for previously treated advanced hepatocellular carcinoma [TA555] is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Darvadstrocel for treating complex perianal fistulas in Crohn's disease [TA556] is not recommended by NICE. **Traffic Light: BLACK**

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA557) is recommended as an option by NICE. Approved in line with NICE.
Cancer Drugs Fund **Traffic Light: RED**

Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558) is recommended as an option by NICE. Approved in line with NICE.
Cancer Drugs Fund **Traffic Light: RED**

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559) is recommended as an option by NICE. Approved in line with NICE.
Cancer Drugs Fund **Traffic Light: RED**

2019/032: EAMS (Early Access to Medicines Scheme)

Dupixent is being made available to adolescent patients ≥ 12 to < 18 years of age with severe atopic dermatitis who have responded inadequately to at least one systemic therapy or where the available systemic therapies are not recommended or are not tolerated – inclusion on EAMS acknowledged.

STANDING ITEMS

2019/033: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Jan 2019
Minutes acknowledged

2019/034: FOR ACTION/INFORMATION: LANCASHIRE CARE FOUNDATION TRUST D & T MINUTES – Jan 2019
Minutes acknowledged

2019/035: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Nov 2018
Minutes acknowledged

ADDITIONAL ITEM

LMWH for prophylaxis – due to an international shortage of tinzaparin (prophylaxis strength syringes) the trust will be changing the LMWH (low molecular weight heparin) that is used for prophylaxis to enoxaparin (Inhixa® brand) from next week. An updated 'LMWH Best Practice Guideline' is in preparation and will be brought to next ELMMB.

DATE OF NEXT MEETING – Wednesday 20th March 2019 12.00noon, Board Room, Trust Headquarters, Level 2, RBH

Dates for 2019: All 3rd Wednesday of the month starting at 12 noon

20th March

17th April

15th May

19th June

17th July

21st August

18th September

16th October

20th November

18th December

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 20TH FEBRUARY 2019

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2018/164	Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance®, Clinitas Multi® - further information being prepared by ophthalmology to discuss.	CW	Jan 19
2019/007	LMMG Recommendations (from Dec LMMG) - Choice of DOAC for stroke prevention in AF Position Statement to be combined with a memo from LMMG.	LR/JV	Feb 19
2019/025	ELHE: Respiratory Guidelines – Updated COPD guideline – to be amended in line with comments	JV	Mar 19
2019/027	Antihistamines Prescribing Policy - to be amended in line with comments	JV	Mar 19